Phase I-II Study of MEK 162 for Children with Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors

Brief description of study

If you or your child has been diagnosed with low-grade gliomas, you or your child may qualify to participate in a study evaluating the safety and effectiveness of the investigational drug, MEK162, a dual specific kinase inhibitor, which blocks a critical regulator in a key pathway that helps control cells' ability to grow and survive.  The main goal of this phase I-II study is to find out what effects, good and/or bad, MEK162 has on people with low-grade gliomas.  In addition, we would like to explore the pharmacodynamic effect of the investigational drug, MEK162 on biomarkers (proteins) of a specific signaling pathway.  This study will be conducted in two phases:  Phase I will consist of defining the toxicity profile of the investigational drug.  Phase II will help determine how the investigational drug reacts to your cancer.


Clinical Study Identifier: s17-00228
ClinicalTrials.gov Identifier: NCT02285439
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.